This is a phase 3, randomized, multicenter, double-masked, parallel group, vehicle-controlled prospective clinical trial to evaluate the safety and efficacy of…

Persistent Corneal Epithelial Defect

~Estimated

~$10 – $7,500

Dompé Farmaceutici S.p.ANCT07519902

Phase 2

A Randomized, Multicenter, Double-Masked, Vehicle-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With Persistent Corneal Epithelial Defects (NEXPEDE-1)

This study is to evaluate the safety and efficacy of NEXAGON® (lufepirsen ophthalmic gel) (NEXAGON) in subjects with persistent corneal epithelial defects (PCE…

Persistent Corneal Epithelial Defect

~Estimated

~$10 – $8,750

Glaukos CorporationNCT05966493

Phase 2

Phase II Study of the Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease

In this phase II randomized double-masked clinical trials, subjects with non-resolving corneal epithelial disease/defect (i.e., refractory to standard treatmen…

Persistent Corneal Epithelial DefectCorneal Epithelial Disorders

~Estimated

~$10 – $6,250

University of Illinois at ChicagoNCT06919081